8-K - NUTX - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December21, 2022

NUTEX

HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-53862	11-3363609
(State<br> or Other Jurisdiction<br><br> of Incorporation)	(Commission<br> File Number)	(I.R.S.<br> Employer<br><br> Identification Number)

‎

6030S. Rice Ave**, SuiteC** , Houston ,Texas

77081

(Address of principal executive offices) (zip code)

‎(713)

660-0557‎

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title<br> of each class	Trading<br> Symbols(s)	Name<br> of each exchange on which registered
Common Stock, $0.001 par value	NUTX	The NASDAQStock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

| 1 |

| --- |

Item 7.01Regulation FD Disclosure.

On December 21, 2022, Nutex Health Inc. (the “Company”) issued a press release announcing that Tom Vo, M.D., MBA (CEO and Chairman), Warren Hosseinion, M.D. (President) and Jon Bates (CFO) are scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023. A copy of the Press Release is furnished as Exhibit 99.2 A copy of the Company’s presentation is furnished as Exhibit 99.2.

Item 9.01 Financial Statementsand Exhibits

(d) Exhibits

Exhibit No.	Description of Exhibit
99.1	Press Release dated December 21, 2022.
99.2	Nutex Health Inc. Investor Presentation.
104	Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

THE INFORMATION CONTAINED IN ITEM 2.02 OF THIS CURRENT REPORT, INCLUDING EXHIBITS 99.1 AND 99.2 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING.

| 2 |

| --- |

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: December 21, 2022

NutexHealth Inc.

By: /s/ Jon C. Bates

Jon C. Bates

Chief Financial Officer

| 3 |

| --- |

NUTEX HEALTH to presentat the 41^st^ Annual J.P. Morgan Healthcare conference

HOUSTON, TX − (PRNewswire) – DECEMBER 21,2022 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced that Tom Vo, M.D., MBA (CEO and Chairman), Warren Hosseinion, M.D. (President) and Jon Bates (CFO) are scheduled to present at the 41^st^ Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 12, 2023.

41^st^ Annual J.P. Morgan Healthcare Conference(January 9-12, 2023)

Presentation Date/Time:	January 12, 2023 at 7:30am PST/10:30am EST
Venute:	Elizabethan Room C
	Westin St. Francis Hotel
	335 Powell St.
	San Francisco, CA 94102

The management team will also host 1x1 meetings with institutional investors and equity analysts during the week. The Company’s investor presentation has been provided in a Current Report on Form 8-K which has been filed with the Securities & Exchange Commission (“SEC”) and available at www.sec.gov and https://www.nutexhealth.com/investor-presentations.

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops, and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in 8 states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.

Forward-Looking Statements

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-Q for the period ended September 30, 2022 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

FOR ADDITIONAL INFORMATION:

Nutex Health, Inc.

Vivian Sanders – Investor Relations

investors@nutexhealth.com

Jennifer Smith Rodriguez – Media Contact

jsmith@nutexhealth.com

Nutex Helath Presentation